The Company’s lead compound is progressing through remaining preclinical studies and is targeting IND submission for AD in late 2021, with follow on studies being planned in one of the rare disease tauopathies (DART program noted in pipeline graphic). The Company has recently begun to characterize its 2nd generation series of small molecule tau aggregation inhibitors.